1. Garg, A, Lavian, J, Lin, G, et al. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol 2017; 77: 118–122.
Google Scholar | Crossref | Medline2. Daxhelet, M, Suppa, M, White, J, et al. Proposed definitions of typical lesions in hidradenitis suppurativa. Dermatology 2020; 236: 431–438.
Google Scholar | Crossref | Medline3. Nguyen, TV, Damiani, G, Orenstein, LAV, et al. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021; 35: 50–61.
Google Scholar | Crossref | Medline4. Sabat, R, Jemec, GBE, Matusiak, Ł, et al. Hidradenitis suppurativa. Nat Rev Dis Primers 2020; 6: 18.
Google Scholar | Crossref | Medline5. González-Manso, A, Agut-Busquet, E, Romaní, J, et al. Hidradenitis suppurativa: proposal of classification in two endotypes with two-step cluster analysis. Dermatology 2021; 237: 365–371.
Google Scholar | Crossref | Medline6. von der Werth, JM, Williams, HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000; 14: 389–392.
Google Scholar | Crossref | Medline7. Narla, S, Azzam, M, Townsend, S, et al. Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. Br J Dermatol 2021; 184: 1004–1013.
Google Scholar | Crossref | Medline8. Zouboulis, CC, Benhadou, F, Byrd, AS, et al. What causes hidradenitis suppurativa ? 15 years after. Exp Dermatol 2020; 29: 1154–1170.
Google Scholar | Crossref | Medline9. Alikhan, A, Sayed, C, Alavi, A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 2019; 81: 76–90.
Google Scholar | Crossref | Medline10. Ingram, JR, Collier, F, Brown, D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa)2018. Br J Dermatol 2019; 180: 1009–1017.
Google Scholar | Crossref | Medline11. Hurley, H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk, RK, Roenigk, HH (eds) Dermatologic surgery: principles and practice. New York: Marcel Dekker, 1989, pp. 729–739.
Google Scholar12. Horváth, B, Janse, IC, Blok, JL, et al. Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group. Acta Derm Venereol 2017; 97: 412–413.
Google Scholar | Crossref | Medline13. Kimball, AB, Sobell, JM, Zouboulis, CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol 2016; 30: 989–994.
Google Scholar | Crossref | Medline14. Zouboulis, CC, Tzellos, T, Kyrgidis, A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017; 177: 1401–1409.
Google Scholar | Crossref | Medline15. Tricarico, PM, Boniotto, M, Genovese, G, et al. An integrated approach to unravel hidradenitis suppurativa etiopathogenesis. Front Immunol 2019; 10: 892.
Google Scholar | Crossref | Medline16. Jfri, AH, O’Brien, EA, Litvinov, IV, et al. Hidradenitis suppurativa: comprehensive review of predisposing genetic mutations and changes. J Cutan Med Surg 2019; 23: 519–527.
Google Scholar | SAGE Journals17. Wang, Z, Yan, Y, Wang, B. γ-secretase genetics of hidradenitis suppurativa: a systematic literature review. Dermatology 2021; 237: 698–704.
Google Scholar | Crossref | Medline18. Vekic, DA, Frew, J, Cains, GD. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1. Australas J Dermatol 2018; 59: 267–277.
Google Scholar | Crossref | Medline19. Frew, JW, Vekic, DA, Woods, J, et al. A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa. Br J Dermatol 2017; 177: 987–998.
Google Scholar | Crossref | Medline20. Vellaichamy, G, Dimitrion, P, Zhou, L, et al. Insights from γ-secretase: functional genetics of hidradenitis suppurativa. J Invest Dermatol 2021; 141: 1888–1896.
Google Scholar | Crossref | Medline21. Wang, B, Yang, W, Wen, W, et al. Gamma-secretase gene mutations in familial acne inversa. Science 2010; 330: 1065.
Google Scholar | Crossref22. Nomura, T . Hidradenitis suppurativa as a potential subtype of autoinflammatory keratinization disease. Front Immunol 2020; 11: 847.
Google Scholar | Crossref | Medline23. González-Villanueva, I, Gutiérrez, M, Hispán, P, et al. Novel POFUT1 mutation associated with hidradenitis suppurativa-Dowling-Degos disease firm up a role for Notch signalling in the pathogenesis of this disorder. Br J Dermatol 2018; 178: 984–986.
Google Scholar | Crossref | Medline24. Pavlovsky, M, Sarig, O, Eskin-Schwartz, M, et al. A phenotype combining hidradenitis suppurativa with Dowling-Degos disease caused by a founder mutation in PSENEN. Br J Dermatol 2018; 178: 502–508.
Google Scholar | Crossref | Medline25. Garcovich, S, Tricarico, PM, Nait-Meddour, C, et al. Novel nicastrin mutation in hidradenitis suppurativa-Dowling-Degos disease clinical phenotype: more than just clinical overlap? Br J Dermatol 2020; 183: 758–759.
Google Scholar | Crossref | Medline26. Vural, S, Gundogdu, M, Kundakci, N, et al. Familial Mediterranean fever patients with hidradenitis suppurativa. Int J Dermatol 2017; 56: 660–663.
Google Scholar | Crossref | Medline27. Vural, S, Gündoğdu, M, Gökpınar İli, E, et al. Association of pyrin mutations and autoinflammation with complex phenotype hidradenitis suppurativa: a case-control study. Br J Dermatol 2019; 180: 1459–1467.
Google Scholar | Crossref | Medline28. Calderón-Castrat, X, Bancalari-Díaz, D, Román-Curto, C, et al. PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Br J Dermatol 2016; 175: 194–198.
Google Scholar | Crossref | Medline29. Marzano, AV, Trevisan, V, Gattorno, M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 2013; 149: 762–764.
Google Scholar | Crossref | Medline30. Marzano, AV, Damiani, G, Ceccherini, I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol 2017; 176: 1588–1598.
Google Scholar | Crossref | Medline31. Boer, J, Jemec, GBE. Mechanical stress and the development of pseudo-comedones and tunnels in hidradenitis suppurativa/acne inversa. Exp Dermatol 2016; 25: 396–397.
Google Scholar | Crossref | Medline32. Shlyankevich, J, Chen, AJ, Kim, GE, et al. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014; 71: 1144–1150.
Google Scholar | Crossref | Medline33. Gold, DA, Reeder, VJ, Mahan, MG, et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014; 70: 699–703.
Google Scholar | Crossref | Medline34. Danby, FW . Diet in the prevention of hidradenitis suppurativa (acne inversa). J Am Acad Dermatol 2015; 73(5, Suppl. 1): S52–S54.
Google Scholar | Crossref | Medline35. Garg, A, Papagermanos, V, Midura, M, et al. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol 2018; 178: 709–714.
Google Scholar | Crossref | Medline36. Karagiannidis, I, Nikolakis, G, Sabat, R, et al. Hidradenitis suppurativa/acne inversa: an endocrine skin disorder? Rev Endocr Metab Disord 2016; 17: 335–341.
Google Scholar | Crossref | Medline37. Tzellos, T, Zouboulis, CC. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther 2020; 10: 63–71.
Google Scholar | Crossref38. Langan, EA, Recke, A, Bokor-Billmann, T, et al. The role of the cutaneous microbiome in hidradenitis suppurativa – light at the end of the microbiological tunnel. Int J Mol Sci 2020; 21: 1205.
Google Scholar | Crossref | Medline39. Ring, HC, Bay, L, Nilsson, M, et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol 2017; 176: 993–1000.
Google Scholar | Crossref | Medline40. Prens, E, Deckers, I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol 2015; 73(5, Suppl. 1): S8–S11.
Google Scholar | Crossref | Medline41. Seyed Jafari, SM, Hunger, RE, Schlapbach, C. Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm. Front Med 2020; 7: 68.
Google Scholar | Crossref42. Goldburg, SR, Strober, BE, Payette, MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2020; 82: 1045–1058.
Google Scholar | Crossref | Medline43. van der Zee, HH, de Ruiter, L, van den Broecke, DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292–1298.
Google Scholar | Crossref | Medline44. Witte-Händel, E, Wolk, K, Tsaousi, A, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol 2019; 139: 1294–1305.
Google Scholar | Crossref | Medline45. Lu, JD, Milakovic, M, Ortega-Loayza, AG, et al. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opin Investig Drugs 2020; 29: 1179–1185.
Google Scholar | Crossref | Medline46. Zouboulis, CC, Frew, JW, Giamarellos-Bourboulis, EJ, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol 2021; 30(Suppl. 1): 8–17.
Google Scholar | Crossref | Medline47. Giamarellos-Bourboulis, EJ, Argyropoulou, M, Kanni, T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol 2020; 183: 176–178.
Google Scholar | Crossref | Medline48. Balato, A, Caiazzo, G, Annunziata, MC, et al. Anti-TNF-α therapy modulates mTORC1 signalling in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019; 33: e43–e45.
Google Scholar | Crossref | Medline49. Jiménez-Gallo, D, de la Varga-Martínez, R, Ossorio-García, L, et al. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa. Cytokine 2018; 103: 20–24.
Google Scholar | Crossref | Medline50. Matusiak, Ł, Szczęch, J, Bieniek, A, et al. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol 2017; 76: 670–675.